% 0期刊文章% Cinzia Cordioli %一个萨拉Rasia尼古拉德罗西% %朱塞佩•Santuccio %另·卡普拉% T利妥昔单抗治疗后高度活跃的多发性硬化症(MS) Natalizumab-Related渐进多焦点的脑白质病(PML) (P6.166) % D J神经病学2016% % P P6.166 X % V % 86% N 16补充报告一个年轻女子受到多发性硬化症与严重疾病复活后由于PML natalizumab撤军。首页活跃的女士随后接受利妥昔单抗。背景:natalizumab女士非常有效,但与PML的风险,脱髓鞘感染中枢神经系统(CNS)由JC多瘤病毒引起的。Natalizumab撤军PML的发生是强制性的,但恶劣的活化可能发生和一个女士immunomodulant疗法必须恢复。设计方法:PML发生在2014年10月后48 natalizumab注入;12月,immuno-reconstitution后,病人临床女士复活了几个新的钆增强MRI在大脑和脊髓损伤;eds恶化从四个(基线)7。fingolimod上一个月之后,一个新的严重复发发生(eds 8.5 -新MRI活动病变);2015年2月fingolimod停止了。美罗华在2015年5月推出和三个注入(两个2015年5月,2015年9月,根据淋巴细胞CD19计数)管理; a better clinical condition was obtained until October 2015 (EDSS 5.5). Results: rituximab led to the clinical MS remission and MRI stability without the PML relapse. Conclusions: Therapy with rituximab might be an option in treatment of MS patients with severe active MS disease, after Natalizumb - PML. To our knowledge, this is the first described case with a one-year follow-up.Disclosure: Dr. Cordioli has received personal compensation for activities with Genzyme and Biogen Idec. Dr. De Rossi has nothing to disclose. Dr. Rasia has nothing to disclose. Dr. Santuccio has received personal compensation from Novartis and Teva for activities as a speaker. Dr. Ruggero Capra has nothing to disclose.Thursday, April 21 2016, 8:30 am-5:30 pm %U